Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Phase 2, Safety, and Efficacy Study of Ruxolitinib Cream in Participants With Genital Vitiligo

NCT05750823 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT05750823
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05750823 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Phase 2, Safety, and Efficacy Study of Ruxolitinib Cream in Participants With Genital Vitiligo
Lead sponsor
Incyte Corporation
Phase
Phase 2
Overall status
Completed
Start date
April 11, 2023
Completion date
March 6, 2025
Enrollment
49 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

nonsegmental vitiligo with genital involvement